Greenwich LifeSciences (NASDAQ:GLSI) Given New $39.00 Price Target at HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI - Free Report) had its price target raised by HC Wainwright from $38.00 to $39.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Greenwich LifeSciences' Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.94) EPS.

Greenwich LifeSciences Stock Down 4.4 %

Greenwich LifeSciences stock traded down $0.46 during trading hours on Monday, hitting $9.98. The stock had a trading volume of 62,962 shares, compared to its average volume of 45,347. The business's 50 day simple moving average is $10.63 and its 200-day simple moving average is $12.24. Greenwich LifeSciences has a one year low of $8.06 and a one year high of $18.75. The stock has a market cap of $132.47 million, a price-to-earnings ratio of -12.47 and a beta of 1.76.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.40). Research analysts anticipate that Greenwich LifeSciences will post -0.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 3,600 shares of the business's stock in a transaction on Monday, April 7th. The shares were purchased at an average cost of $9.10 per share, for a total transaction of $32,760.00. Following the acquisition, the chief executive officer now owns 5,561,602 shares of the company's stock, valued at approximately $50,610,578.20. This represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders acquired 14,500 shares of company stock worth $129,267. Company insiders own 51.67% of the company's stock.

Hedge Funds Weigh In On Greenwich LifeSciences

Institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company's stock valued at $1,026,000 after buying an additional 3,005 shares in the last quarter. Barclays PLC grew its position in shares of Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company's stock valued at $123,000 after acquiring an additional 6,538 shares during the period. Geode Capital Management LLC increased its position in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after buying an additional 5,861 shares during the last quarter. Garden State Investment Advisory Services LLC purchased a new stake in Greenwich LifeSciences in the 3rd quarter worth about $253,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock worth $79,000 after purchasing an additional 4,465 shares in the last quarter. Institutional investors and hedge funds own 4.16% of the company's stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.